The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: A comparison of Markov model and trial data estimates

American Journal of Managed Care

Volumn 4, Issue 7, 1998, Pages 1004-1012

  Mauskopf, Josephine ^a   Lacey, Loretto ^b   Kempel, Angela ^c   Simpson, Kit ^d  

^a RTI INTERNATIONAL   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Pharmametrics GmbH   (Germany)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ZIDOVUDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MARKOV CHAINS; MODELS, ECONOMETRIC; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES; ZIDOVUDINE;

EID: 0031828951     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hellinger F. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-478.
2. Simpson K, Hatziandreu E, Andersson F, et al. Cost-effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/μl in 5 European countries. PharmacoEconomics 1994; 6:553-562.
3. Moore R, Bartlett J. Combination antiretroviral therapy in HIV infection: An economic perspective. PharmacoEconomics 1996;10:109-113.
4. Paltiel A, Scharfstein J, Seage G, et al. A Monte Carlo simulation of advanced HIV disease: Application to prevention of CMV infection. Med Decis Making 1998;18(suppl): S93-S105.
5. Johannesson M, Weinstein M. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-467.
6. Schulman K, Lynn L, Glick H, et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.
7. Moore R, Hidalgo J, Bareta J, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7:349-354.
8. Cook J, Dasbach E, Coplan P, et al. Using HIV viral RNA to estimate the cost-effectiveness of indinavir alone and in combination. Paper presented at: 4th Conference on Retroviruses and Opportunistic Infections; January 23-26, 1997; Washington DC.
9. Mellors J, Kingsley L, Gupta P, et al. Prognostic value of plasma HIV-1 RNA quantification in sero-positive adult men. Program and abstracts of XI International Conference on AIDS; July 6-11 1996; Vancouver, Canada. Abstract We.B.410.
10. Yerly S, Pernager T, Hirschel B, et al. HIV viremia influences survival in HIV-infected patients. Program and abstracts of XI International Conference on AIDS; July 6-11 1996; Vancouver, Canada. Abstract We.B.413.
11. Choo V. Combination superior to zidovudine in Delta trial. Lancet 1995;346:895.
12. Gazzard B, on behalf of the International Coordinating Committee. Further results from European/Australian DELTA trial. Program and abstracts of the 3rd Annual Conference of Retroviruses and Opportunistic Infections; January 28-31, 1996; Washington, DC. Abstract LB5a.
13. Katzenstein D, Hammer S, Hughes M, et al. Suppression of plasma HIV RNA by reverse transcriptase inhibitor prevents AIDS and death in ACTG 175; combination and monotherapy with ZDV, DDI, and DDC. Program and abstracts of XI International Conference on AIDS; July 6-11, 1996; Vancouver, Canada. Abstract Mo.B.293.
14. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 1997;349:1413-1421.
15. Simpson KN. Design and assessment of cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr 1995;10(suppl 4): S28-S32.
16. Oddone E, Cowper P, Hamilton J, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. Br Med J 1993;307:1322-1325.
17. Hlatky M. Using databases to evaluate therapy. Stat Med 1991;10:647-652.
18. Weinstein M. Economic assessments of medical practices and technologies. Med Decis Making 1981;1:309-330.
19. Pauker S, Kassirer J. Decision analysis. N Engl J Med 1987;316:250-258.
20. Trueman R. Quantitative Methods for Decision Making in Business. Chicago, IL: The Dryden Press; 1981:597-601.
21. Staszewski S, Loveday C, Picazo J, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine experienced patients: A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276:111-117.
22. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-125.
23. Wiewora R, Stratogen L. Persistence of CD4 lymphocyte increases at 18 months of treatment with lamivudine. Paper presented at: XI International Conference on AIDS; July 1996; Vancouver, Canada. Abstract Mo.B.1133.
24. Andrulis D, Weslowski V, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992;267:2482-2486.
25. US Bureau of the Census. Statistical Abstract of the United States: 1996. 116th ed. Washington, DC: US Bureau of the Census; 1996:494, Table 762.
26. Tsevat J, Solzan J, Kuntz K, et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care 1996;34:44-57.
27. Gold M, Siegel J, Russell L, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:233.
28. Maryland Health Services Cost Review Commission (HSCRC). Nonconfidential inpatient and outpatient surgery discharge data for 1994. St Paul Computer Center. 300 Hospital Drive, Suite 30. Clem Burnie, MD 21061.
29. Physicians Desk Reference. 51st ed. Montvale, NJ: Medical Economics Data; 1997.
30. Garrett H, ed. 1995 Red Book. Montvale, NJ: Medical Economics Data; August 1995.
31. Mark D, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
32. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost-effectiveness of lamivudine-zidovudine combination therapy in HIV infection. PharmacoEconomics 1997 12(1):54-66.
33. Rose D, Sacks H. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: Oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997;11:883-887.
34. Carpenter C, Fischl M, Hammer S, et al. Antiviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277: 1962-1969.